Condition: Systemic Lupus Erythematosus · Sponsor: HC Biopharma Inc.
The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects. Secondary objectives of study are as follows: To estimate the PK parameters of single-ascending SC doses of HC022 in healthy subjects；To evaluate the immunogenicity of HC022 administered to healthy subjects.
This description comes directly from the study's public registry record.
Langxi Zhang, PhD · 8602150433368 · langxi.zhang@btyy.com
The Clinical Pharmacology Research Center of PUMCH
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital | Beijing, China | Not Yet Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Recruiting |
| The Clinical Pharmacology Research Center of PUMCH | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06657703